Antibiotic Stewardship

CDC and NJDOH work to improve antibiotic use in inpatient healthcare settings, such as acute-care facilities, through the implementation of antibiotic stewardship programs designed to ensure that hospitalized patients receive the right antibiotic, at the right dose, at the right time, and for the right duration.

Antimicrobial stewardship interventions have been proven to improve individual patient outcomes, reduce the overall burden of antibiotic resistance, and save healthcare dollars. If everyone — healthcare providers, hospital administrators, policy makers, and patients — works together to employ effective antibiotic stewardship programs, we can improve patient care, more effectively combat antibiotic resistance and ultimately save lives.

Educational Materials

Resources for Healthcare Providers

Resources for Correctional Facilities

Resources for Healthcare Facilities

Disease Prevention

Antibiotic Stewardship Programs

 

CDC's National Healthcare Safety Network (NHSN)

NHSN is the primary healthcare-associated infection (HAI) tracking system in New Jersey and the nation. NHSN can be used to track MRSA, C. difficile, and other multidrug-resistant organisms within healthcare facilities.

 

C. Difficile

 

Methilin-resistant Staphylococcus aureus (MRSA)

MRSA reporting into NHSN is currently required for all acute care hospitals in New Jersey. At a minimum, each facility must be monitoring MRSA LabID Event BSIs at the facility-wide level and conducting MRSA Admission AST to and the adherence rate in at least one high-risk patient care area (i.e., a patient care area where patients have an increased likelihood of acquiring MRSA and/or developing severe clinical outcomes resulting from a MRSA infection).

Drug-resistant N. Gonorrhoeae

VISA/VRSA

Staphylococcus aureus with intermediate-level (VISA) or high-level resistance (VRSA) to vancomycin are must be reported to the local department of health within 24 hours of diagnosis. VISA is S. aureus with a vancomycin MIC >= 4 ug/ml; VRSA is S. aureus with a vancomycin MIC >= 16 ug/ml. Susceptibility levels are defined by according to Clinical and Laboratory Standards Institute's Performance Standards for Antimicrobial Susceptibility Testing; Seventeenth Informational Supplement (M100-S17).

VRE

 

NJ Antibiotic Stewardship Recognition Program

Coming Soon!

Last Reviewed: 4/15/2019